Form 4: Emergent BioSolutions Executive Reports Stock Transaction
SEC Form 4 Filing
Coleen Glessner, EVP at Emergent BioSolutions, reports disposition of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On April 7, 2025, Coleen Glessner, an Executive Vice President at Emergent BioSolutions Inc., disposed of 480 shares of common stock to cover tax obligations.
- The shares were disposed of at a price of $4.44 per share.
- Following the transaction, Glessner directly owns 176,176 shares of Emergent BioSolutions Inc.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a routine stock transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a routine disclosure of insider transactions, which are common and legal as long as they comply with SEC regulations. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders as it is a routine sale of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 04/07/2025 | Date of stock transaction |
| 04/09/2025 | Date of signature |
Keywords
Emergent BioSolutions, EBS, Form 4, Insider Trading, Stock Transaction, Coleen Glessner, Executive Vice President, Restricted Stock Units, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.